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Abstract
Background: Drug resistance is a primary hindrance for the efficiency of chemotherapy against
osteosarcoma. Although chemotherapy has improved the prognosis of osteosarcoma patients
dramatically after introduction of neo-adjuvant therapy in the early 1980's, the outcome has since
reached plateau at approximately 70% for 5 year survival. The remaining 30% of the patients
eventually develop resistance to multiple types of chemotherapy. In order to overcome both the
dose-limiting side effects of conventional chemotherapeutic agents and the therapeutic failure
incurred from multidrug resistant (MDR) tumor cells, we explored the possibility of loading
doxorubicin onto biocompatible, lipid-modified dextran-based polymeric nanoparticles and
evaluated the efficacy.
Methods: Doxorubicin was loaded onto a lipid-modified dextran based polymeric nano-system.
The effect of various concentrations of doxorubicin alone or nanoparticle loaded doxorubicin on
KHOS, KHOSR2, U-2OS, and U-2OSR2  cells was analyzed. Effects on drug retention,
immunofluorescence, Pgp expression, and induction of apoptosis were also analyzed.
Results:  Dextran nanoparticles loaded with doxorubicin had a curative effect on multidrug
resistant osteosarcoma cell lines by increasing the amount of drug accumulation in the nucleus via
Pgp independent pathway. Nanoparticles loaded with doxorubicin also showed increased apoptosis
in osteosarcoma cells as compared with doxorubicin alone.
Conclusion: Lipid-modified dextran nanoparticles loaded with doxorubicin showed pronounced
anti-proliferative effects against osteosarcoma cell lines. These findings may lead to new treatment
options for MDR osteosarcoma.
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Background
Osteosarcoma is the most common primary malignant
bone tumor in children and adolescents and accounts for
approximately 60% of primary malignant bone tumors
diagnosed in the first two decades of life [1]. Standard
treatment for osteosarcoma is a combination of surgery
and chemotherapy. The cure rate of patients with local-
ized osteosarcoma ranges from 15 to 20% with surgery
alone, but improves to approximately 70% when com-
bined with chemotherapy [2]. Unfortunately, for the 40%
of patients with progression of osteosarcoma after front-
line therapy, further therapy with additional chemother-
apy is palliative and toxic. It is estimated that less than
30% of patients with recurrent disease will be cured [2-4].
Cancer cells employ a host of different mechanisms to
become resistant to one or more chemotherapeutic
agents. It is known that multidrug resistance (MDR) can
occur due to the following potential reasons: enhanced
detoxification of the drugs through increased metabolism,
decrease in drug uptake, a reaction with increased levels of
intracellular nucleophiles, enhanced repair of the drug-
induced damage to DNA [5], or through overexpression of
membrane-bound drug transporter proteins, such as P-
glycoprotein (Pgp, ABCB1), multidrug resistance-associ-
ated proteins (MRP1, ABCC1 and MRP2, ABCC2) and the
breast cancer resistance protein (BCRP, ABCG2) [6]. The
development and discovery of agents that reverse MDR
with high efficiency and low toxicity has been the focus of
extensive research [7-10]. Unfortunately, these com-
pounds are often nonspecific and have low efficiency and/
or high toxicity; as such, phase 3 clinical trials of these
agents are largely disappointing [7,8,11-14]. Successful
management of osteosarcoma would be greatly aided by
novel agents that interfere with both intrinsic and
acquired mechanisms of drug resistance mechanisms.
To overcome drug resistance and reduce the side effects
during chemotherapy, nanotechnology holds promising
potential, utilizing targeted drug delivery [15]. Varieties of
nanoparticles are available [16]: polymeric nanoparticles,
dendrimers, inorganic/metal nanoparticles, quantum
dots, liposomes, micelles, and several other types of nano-
assemblies. Polymeric nanoparticle based delivery sys-
tems offer a significant advantage over other nano-carrier
platforms as there is tremendous versatility in choice of
polymer matrices that can be used, which allows for the
tailoring of nanoparticle properties to meet the specific
needs they were intended to meet. Other advantages
include ease in surface modification, greater encapsula-
tion efficiency of the payload, payload protection, large
surface area-to-volume ratio, and slow or fast polymer
erosion for temporal control over the release of drugs
[17].
Dextran is a polysaccharide mainly composed of 1,6-
linked D-glucopyranose residues. There are several advan-
tages of using dextran as a macromolecular carrier for
chemotherapeutic applications because it is biocompati-
ble and inert. Due to its biocompatibility and biodegrad-
ability, dextran and its derivatives have been widely used
as blood substitutes and drug carriers [18]. Much work has
been carried out to realize useful properties for dextran via
various chemical modifications for specific applications,
especially its use as a polymeric drug carrier [19,20]. Low
molecular weight conjugates of dextran have the advan-
tage of reduced side effects, however its therapeutic poten-
tial is not optimum, due to its relatively short plasma half-
life [21]. Therefore, in this study, we have used high
molecular weight dextran-lipid nanoparticles to encapsu-
late doxorubicin.
Although the drug resistance in osteosarcoma is well
known, there is hardly any study that addresses the effect
of drug-loaded nanoparticle formulation on drug-resist-
ant osteosarcoma cells. In order to overcome both the
dose-limiting side effects of conventional chemothera-
peutic agents and the therapeutic failure incurred from
MDR tumor cells, we have undertaken the rational design
of biocompatible dextran based polymeric nanoparticles
for the sustained delivery of doxorubicin.
Methods
Chemicals
Dextran (Mw~40 kDa), stearyl amine (99% pure),
cystamine, pyridine, sodium periodate (NaIO4), sodium
cyanoborohydride (NaCNBH3), and potassium sulfate
(K2SO4)  and azo-bis-isobutyronitrile (AIBN) were
obtained from Sigma-Aldrich Chemical Co (St. Louis,
MO). Dithiol-modified poly(ethylene glycol) (PEG-
(SH)2, M.W. 2,000) was purchased from SunBio, Inc.
(Seoul, South Korea). Anhydrous lithium chloride (LiCl)
was from Fisher Scientific (Philadelphia, PA). Dehydrated
dimethylformamide (DMF) and dimethylsulfoxide
(DMSO) with molecular sieves was obtained from Acros
Organics (Parsipanny, NJ). Acryloyl chloride, pyridine
and other reagents and solvents were from Sigma-Aldrich
and were used as received without further purification.
Synthesis of lipid-modified dextran polymer
Synthesis of dextran acrylate
The synthesis of dextran acrylate was based on the proce-
dure of Zhang et al. [22]. Briefly, a fixed amount of dex-
tran (M.W. ~40 kDa, 2 g) was added to a LiCl/DMF (4%
w/v, 50 ml) solvent mixture in a round bottom flask (200
ml). The temperature of the oil bath was raised from room
temperature to 120°C over a period of 2 h. The resultant
mixture became a homogeneous golden yellow solution.
The solution was cooled to room temperature, and pyrid-
ine (500 μl) was added and stirred. The reaction mixtureBMC Cancer 2009, 9:399 http://www.biomedcentral.com/1471-2407/9/399
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was cooled to 0°C using ice bath and varying amounts of
acryloyl chloride (1-1.5 molar excess) was added drop
wise using an addition funnel. The reaction was main-
tained at 0°C until complete addition of acryloyl chloride
was done over a period of 1-2 h. The reaction was allowed
to continue overnight. The dextran-acrylate obtained was
precipitated in excess cold ethanol and washed three
times with absolute ethanol. For confirmation of the for-
mation of dextran acrylate, a small portion of the acrylate
monomer was polymerized using 0.001% AIBN initiator
in DMSO at 60°C for 24 hours, which resulted in forma-
tion of the acrylate polymer, confirming the reaction.
Alternately, for lipid modification, the dextran-acrylate
obtained in step 1 was directly used as the monomer for
the next step, in a one-pot synthesis.
Lipid modification of dextran acrylate
A desired amount (200 mg) of dextran acrylate obtained
from above step was dissolved in dry DMF and stirred in
a 20 ml glass vial with varying amounts (5-10 mole %) of
stearylamine and a catalyst (0.01 mole % AlCl3). The reac-
tion mixture was heated to 40-50°C in an oil bath for 24
h. The product obtained (stearyl-modified dextran) was
precipitated and washed in cold ethanol several times to
purify the product. Finally, the lipid-modified dextran
derivative was dissolved in small amount of deionized
water and lyophilized to yield the pale yellow final prod-
uct. The stearyl modification of dextran was confirmed by
NMR spectroscopy and the % lipid modification was esti-
mated to be 3-7 mole%.
Synthesis of thiolated dextran
Oxidation of dextran
The dextran backbone was oxidized based on the proce-
dure of Martwiset et al. [23]. Briefly, a desired amount of
NaIO4 was dissolved in 60 ml of deionised water. The
solution was added to another solution containing 4 g of
dextran and 30 ml of de-ionised water. The reaction was
stirred in the dark for 2 h at room temperature. At the end
of the reaction, the solution was dialyzed using Spec-
trapor® dialysis membranes (M.W. cutoff 12-14 kDa, Spec-
trum Labs, Rancho Dominguez, CA) extensively against
de-ionized water (2 L) for 4 days with several water
replacements. A powdery free-flowing sample was
obtained after freeze-drying. Yield: 3.7 g (92.5%).
Thiol modification of dextran
A 500 mg portion of the oxidized dextran was dissolved in
50 ml pH 5.2 buffer containing K2SO4 and NaCNBH3.
Then, 50 mg of cystamine was added and stirred at 40°C
for 4 days. The product was subjected to extensive dialysis
and then lyophilized to yield thiolated-dextran. The per-
cent thiolation was quantified by Ellman's reagent [24].
The concentration of sulfohydryl groups in the purified
thiolated dextran derivate was estimated to be ~14.2 μM/
mg.
Preparation of doxorubicin-containing dextran 
nanoparticles
A stock solution of 5 mg/ml PEG-(SH)2, stearylamine-
modified dextran, and thiolated-dextran synthesized
above were prepared in deionised water. A 10 mM (1 ml)
stock solution of doxorubicin was used for the prepara-
tion of doxorubicin loaded nanoparticle. For preparation
of mixture, 40 μl of dextran-stearyl amine was first added
to a 35 μl (0.35 mM) solution of doxorubicin and mixed
well using a vortex shaker. It was then incubated for 5
minutes. To this mixture, 40 μl dextran-thiol derivative
was added and incubated for another 5 minutes. Finally,
40 μl of PEG-(SH)2 was added and incubated for another
15 minutes to form the hydrophilic shell of the nanopar-
ticles. This method of sequential addition was used so that
there is better interaction between the hydrophobic
groups in doxorubicin and the lipid-modified dextran
derivatives. Since the volume of the sample was small, it
was gently vortexed and no stirring was used. The doxoru-
bicin efficiency and loading in the nanoparticles was
determined by measuring the absorbance of known
amount of sample at 485 nm corresponding to λ max of
doxorubicin and comparing the values to a standard curve
obtained by using a stock solution of doxorubicin.
Particle size and zeta potential measurements
The particle size and zeta potentials of doxorubicin
loaded nanoparticles were performed with the
Brookhaven Zeta PALS Instrument (Holtsville, NY). For
light scattering experiments, the samples were measured
at fixed angle of 90° at 25°C. The scattering intensity was
adjusted in the range of 50-500 kcps by diluting the sam-
ples with deionised water. For zeta potentials, default
parameters of dielectric constant, refractive index, and vis-
cosity of water were used based on the electrophoretic
mobility of the nanoparticles.
Cell culture studies
Human osteosarcoma cell line U-2OS was obtained from
the American Type Tissue Collection (Rockville, MD). Dr.
Efstathios S. Gonos (National Hellenic research Founda-
tion, Athens, Greece) kindly provided the human osteosa-
rcoma cell line KHOS and the multidrug resistant cell
lines KHOSR2, U-2OSR2. All cell lines were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 ug/ml streptomycin
(all obtained from Invitrogen, Carlsbad, CA). Cells were
incubated at 37°C in 5% CO2-95% air atmosphere and
passaged when near confluent monolayers were achieved
using trypsin-EDTA solution. Resistant cell lines were con-
tinuously cultured in 0.1 uM doxorubicin. DoxorubicinBMC Cancer 2009, 9:399 http://www.biomedcentral.com/1471-2407/9/399
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was obtained as unused residual clinical material at the
Massachusetts General Hospital (Bosston, MA).
Cell culture reagents
The Pgp1 monoclonal antibody C219 was purchased
from Signet (Dedham, MA). The human β-actin mono-
clonal antibody and the MTT reagents were purchased
from Sigma-Aldrich (St. Louis, MO).
Quantitative and qualitative evaluation of doxorubicin 
uptake in cells
Flow cytometry
Cell suspensions of KHOS, KHOSR2, U-2OS, and U-2OSR2
incubated with doxorubicin with or without nanoparticle
for 1 hour at 37°C were analyzed for the cellular fluores-
cence in a FACS Calibur flow cytometer (BD Biosciences,
San Jose, CA) with data acquisition using CellQuest soft-
ware. Doxorubicin is intrinsically fluorescent and can be
excited with the 488 nm argon laser light [25]. The cells
were washed and resuspended in PBS and fluorescence
emission (above 530 nm) and forward angle light scatter
were collected, amplified, and scaled to generate histo-
grams. A minimum of 500,000 cells were analyzed for
each histogram generated. Final doxorubicin concentra-
tion used was 10 μM.
Fluorescence microscopy
Cellular uptake studies were based on the procedure of
Venne et al [26]. KHOS and KHOSR2 cells were seeded at
densities of 5 × 105 cells/well in 6 well plates and incu-
bated for 24 h to allow cell attachment. Following the
incubation, either doxorubicin alone or nanoparticle
loaded with doxorubicin was added to each well and were
incubated for additional 3 hours. To counterstain nuclei,
the cells were incubated with 1 μg/ml Hoechst 33342
(Invitrogen, Carlsbad, CA) for 1 minute. After incubation,
the cells were washed and resuspended with PBS and were
then visualized on a Nikon Eclipse Ti-U fluorescence
microscope (Nikon Corp.) equipped with a SPOT RT dig-
ital camera (Diagnostic Instruments, Inc., Sterling
Heights, MI). Fluorescence intensity and cellular localiza-
tion was analyzed at a wavelength of 488 nm in triplicate
different fields at random.
Cytotoxicity assay
In vitro cytotoxity assays were performed by MTT assay as
previously described. Briefly, 3 × 103 cells per well were
plated in 96-well plate during this process. The culture
medium used, RPMI 1640, contained increasing concen-
tration of doxorubicin alone or nanoparticle loaded with
doxorubicin. After culturing for 5 days, 10 μl of MTT (5
mg/ml in PBS) was added to each well and incubated for
3 hr. after dissolving the resulting formazan product with
acid isopropanol, the absorbance (A490) was read on a
SPECTRA max Microplate Spectrophotometer (Molecular
Devices) at a wavelength of 490 nm. Experiment was per-
formed in triplicate. The IC50 was defined as the com-
pound or chemo drug concentration required decreasing
the A490 to50% of the control value.
Western Blot analysis
Pgp1 was analyzed in total cell lysates. Protein lysates
from cells were generated through lysis with 1 × RIPA
Lysis Buffer (Upstate Biotechnology, Charlottesville, VA).
The concentration of the protein was determined by Pro-
tein Assay reagents (Bio-Rad, Hercules, CA) and a spectro-
photometer (Beckman DU-640, Beckman Instruments,
Inc., Columbia, MD). 25 μg of total protein was processed
on Nu-Page 4-12% Bis-Tris Gel (Invitrogen) and trans-
ferred to pure nitrocellulose membrane (Bio-Rad Labora-
tories, Hecules, CA). Primary antibodies were incubated
in Tris-buffered saline, pH7.4, with 0.1% Tween 20 over-
night at 4°C. Signal was generated through incubation
with horseradish peroxidase-conjugated secondary anti-
bodies (Bio-Rad, Hercules, CA) incubated in Tris-buffered
saline, pH 7.4, with 5% nonfat milk and 0.1% Tween 20
at 1: 2000 dilution for 1 h at room temperature. Positive
immunoreactions were detected by using Super Signal®
West Pico Chemiluminescent Substrate (Pierce, Rockford,
IL).
Cellular apoptosis assay
Whole-cell lysates were immunoblotted with specific anti-
bodies to PARP (Cell Signaling Technology) and its cleav-
age products. Positive immunoreactions were detected by
using Super Signal® West Pico Chemiluminescent Sub-
strate. Bands were semiquantified by reverse image scan-
ning densitometry with PhotoShop 7.0 (Adobe, San Jose,
CA). An area of the gel image that was devoid of signal was
assigned to be the background value. Then, each band of
the protein representing cleaved PARP from KHOS or
KHOSR2 treated with either doxorubicin alone or nano-
particle loaded with doxorubicin at various concentra-
tions were analyzed for the density beyond background
level. To ensure that the loading of the protein was equal
and differences were not being observed because of one
specimen having more protein than another, the band
corresponding to β-actin was determined for each protein.
The density of the protein band was normalized to the β-
actin band for the protein and the ratio of the cleaved
PARP was normalized by dividing by the ratio of the actin
corresponding to each cleaved PARP. As a second param-
eter of apoptotic cell death, we measured caspase-3/7
activity in KHOS and KHOSR2 after treatment with either
doxorubicin alone or nanoparticle loaded with doxoru-
bicin by using Apo-ONE Homogenous caspase-3/7 sys-
tem according to the manufacturer's instructions
(Promega, Madison, WI). The intensity of the emitted flu-
orescence was determined at a wavelength of 521 nm withBMC Cancer 2009, 9:399 http://www.biomedcentral.com/1471-2407/9/399
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the use of a SPECTRAmax® Microplate Spectrofluorometer
(Molecular Devices).
Statistical analysis
Values shown are representative of triplicate determina-
tions in two or more experiments. Student's t-test was
used to compare the differences between groups (Graph-
Pad PRISM® 4 software, GraphPad Software, San Diego,
CA). Results are given as mean ± SD and results with p <
0.05 were considered statistically significant.
Results
Lipid-modified dextran nanoparticles for intracellular 
doxorubicin delivery
Doxorubicin was incubated with the lipid-modified dex-
tran derivative in deionized water at RT to form nanopar-
ticles by self-assembled hydrophobic interactions. Further
a thiolated-dextran derivative and PEGylated-thiol deriva-
tive was sequentially mixed with the doxorubicin contain-
ing lipid-modifed dextran derivated to enhance the
binding efficiency of PEG chains to the dextran hydrogel.
This method in fact helped in formation of stable nano-
particles with good doxorubicin loading (Figure 1). The
mean particle size of the doxorubicin-loaded nanoparti-
cles as determined by dynamic light scattering (DLS)
measurement was 112.4 ± 4.2 nm and the zeta potential
was almost neutral (+1.19 ± 0.82 mV). The particles were
stable at room temperature and there was not much
change in the particle size on storage (for 1 week at 4°C).
Enhancement of intracellular doxorubicin accumulation 
with nanoparticle delivery
Lipid-modified dextran nanoparticle caused a significant
increase in the retention of doxorubicin in both KHOSR2
(Figure 2A) and U-2OSR2 (Figure 2B) when examined
through flow cytometry. It was potent enough that the flu-
orescence of drug resistant cells treated with doxorubicin
loaded nanoparticles was comparable to that of drug sen-
sitive cells treated with doxorubicin alone.
Using fluorescent microscopy, subcellular distribution of
doxorubicin in KHOS and KHOSR2 was analyzed. After 3
hour incubation with free doxorubicin in drug resistant
osteosarcoma cells, the drug was primarily concentrated
in the cytoplasm, and a very low level of fluorescence was
observed in the nucleus (Figure 3B). When doxorubicin
was administered with the nanoparticle to drug resistant
cell line, a prominent increase in fluorescence was
observed in the nucleus, whereas the fluorescence of the
cytoplasm remained virtually unaffected (Figure 3C). This
subcellular distribution mimicked that of the drug sensi-
tive variant when treated with doxorubicin (Figure 3A).
Evaluation of anti-proliferative effects in wild-type and 
resistance cells
Dextran nanoparticle was non-cytotoxic by itself at a dose
utilized in this study (Additional file 1). However, we
found that nanoparticles loaded with doxorubicin
showed an increased amount of anti-proliferative activity
in both drug sensitive and resistant osteosarcoma cell
lines in a dose dependent manner (Figure 4A-D). Nano-
particles loaded with doxorubicin showed a 10 fold
higher activity compared to doxorubicin alone against U-
Pictorial representation ofdoxorubicin loaded stearylamine-dextran modified nanoparticles Figure 1
Pictorial representation ofdoxorubicin loaded stearylamine-dextran modified nanoparticles. Thelipid - modified 
dextran forms hydrophobic association withdoxorubicin and the thiol modified dextran interacts with thethiolated\poly (ethyl-
ene glycol) (PEG), forming a core shellstructure, which is further stabilized by the PEG chains.
Doxorubicin + Dextran-Lipid + Dextran-thiol + PEG-(SH)2
PEG
Dextran hydrogel 
network
Doxorubicin
Doxorubicin-loaded dextran
nanoparticlesBMC Cancer 2009, 9:399 http://www.biomedcentral.com/1471-2407/9/399
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2OS (IC50 0.03 μM to 0.3 μM, Figure 4C), 5 fold higher
activity against KHOSR2 (IC50 0.6 μM to IC50 3 μM, Figure
4B), and 20 fold higher activity against U-2OSR2 (IC50 0.3
μM to 6 μM, Figure 4D).
To estimate the effect of nanoparticle on Pgp expression,
we utilized the Western blot assay. Pgp was not expressed
in drug sensitive KHOS and U-2OS, however, Pgp was
overexpressed in the two drug resistant cell lines KHOSR2
and U-2OSR2 (Figure 5). The nanoparticle did not sup-
press the expression of Pgp, but in contrast, the expression
of Pgp gradually increased along with the increase in the
concentration of doxorubicin. These effects were observed
in two different drug resistant osteosarcoma cell lines
(Figure 5).
Induction of cellular apoptosis with doxorubicin 
nanoparticles
To assess the efficacy of nanoparticles loaded with doxo-
rubicin to induce apoptosis on KHOS and KHOSR2, cleav-
age of PARP was detected using western blot assay. The
dextran nanoparticle itself did not cause cleavage of PARP
at a dose utilized in this study (Additional file 2).
Although higher concentration of doxorubicin alone
induced apoptosis, nanoparticles loaded with doxoru-
bicin exhibited a much higher apoptosis induction rate in
both drug sensitive (Figure 6A, C) and resistant cell lines
(Figure 6B, D). In addition, caspase-3/7 activity was sig-
nificantly increased when KHOS and KHOSR2  were
treated with nanoparticles loaded with doxorubicin (Fig-
ure 7A, B).
Discussion
Osteosarcoma is the most common primary malignant
bone tumor among children and adolescents, and
although the prognosis has improved dramatically in the
last 30 years, a plateau in the survival curve has been
reached at approximately 70% for 5-year survival [1,2].
Many studies are undergoing at present including several
phase 3 studies to improve the prognosis of patients, but
have not resulted in drastic improvements. In this report,
a new nanoparticle formulation of co-encapsultaed doxo-
rubicin with high potency has been devised and its effi-
cacy against drug resistant osteosarcoma cell lines has
been examined.
In the clinical setting, we have always faced the problem
of dose limitation, defined as the systemic toxicity of con-
Fluorescence of KHOS, KHOSR2 (A), U-2OS, and U-2OSR2 (B) after treatment with doxorubicin aloneor nanoparticle loaded  with doxorubicin was analyzed by flow cytometry Figure 2
Fluorescence of KHOS, KHOSR2 (A), U-2OS, and U-2OSR2 (B) after treatment with doxorubicin aloneor nano-
particle loaded with doxorubicin was analyzed by flow cytometry. The effect of nanoparticle was potent enough that 
thefluorescence of MDR osteosarcoma cells was comparable to that of drugsensitive variants.
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ventional chemotherapeutics, an issue that can potentiate
the MDR tumor phenotype. A narrow therapeutic index
limits the dose that can be applied at any given single
treatment, causing an uneven dose of treatment and
resulting in some population of tumor cells experiencing
low doses of the applied chemotherapeutic agent. This
essentially promotes the cells for the development of
MDR. Our study demonstrated that nanoparticles loaded
with low concentrations of doxorubicin that will be free of
cellular damage showed stronger and enhanced antipro-
liferative activity against both drug sensitive and resistant
osteosarcoma cell lines.
In order to develop a biocompatible and safe nanopartic-
ulate system for the delivery of doxorubicin, we chose to
synthesize hydrophobically-modified dextran derivates,
which can encapsulate doxorubicn by hydrophobic inter-
actions, similar to the design reported for self-assembled
nanosystems [27]. Further a thiolated-dextran derivative
and PEGylated-thiol derivative was sequentially mixed
with the lipid-modified dextran derivated to enhance the
binding effeciency of PEG chains to the dextran hydrogel.
PEGylated liposomes and nanoparticles can impart
stealth character to the nanoparticles, increase the plasma
residence time, protect the drug payload from degradation
during circulation and also passively target tumor tissues
due to the leakiness of the neovasculature by the
enhanced permeability and retention (EPR) effect [28].
One of the main features of nanoparticles used for drug
delivery is their preferable accumulation in solid tumors
because of the EPR effect [29]. It has been shown that after
administration of nanoparticles without drugs, the EPR
effect in solid tumors primarily arose from differences in
the clearance rate between solid tumor and normal tis-
sues, after an initial penetration of the polymers into these
tissues [30]. This is due to the increased tumor vascular
permeability and the poor lymphatic drainage of the
tumor tissue. It has been reported that nanoparticle
bound drugs is 45-250 times higher in the site of tumors
when compared to other organs such as the liver, kidney,
lung, spleen, or heart [31]. The actual accumulation inside
cells and preservation of drug antitumor activity during its
tissue and subcellular trafficking are also important deter-
minants of the efficacy of an anticancer agent. For anthra-
cyclines in MDR cells, it has been reported that, in
addition to a decrease in the drug accumulation, the intra-
cellular distribution of the drug is changed in human
Subcellular distribution of doxorubicin in drug sensitive and resistant osteosarcoma cell lines was analyzed under fluorescence  microscope (A-C) Figure 3
Subcellular distribution of doxorubicin in drug sensitive and resistant osteosarcoma cell lines was analyzed 
under fluorescence microscope (A-C). A prominent increase in fluorescence was observedin the nucleus when multidrug 
resistant cells were treated withdoxorubicin loaded nanoparticles.
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myeloma [32], myeloid [33], lung tumor cells [34], ovar-
ian carcinoma cells [35], and in epidermoid carcinoma
cells [36]. Anthracycline fluorescence was found mainly in
the nucleus inside sensitive cells and mainly in the cyto-
plasm in cells with a relatively high level of resistance [32-
34,36]. The question was raised whether this was also
applicable to osteosarcoma cell lines. In this study, cellu-
lar uptake and intracellular distribution of doxorubicin
were examined under fluorescence microscopy. Under
immunofluorescence microscope, doxorubicin was pri-
marily accumulated in the nucleus of drug sensitive cells,
and in the cytoplasm of drug resistant cells. When doxo-
rubicin was loaded onto nanoparticles and applied to the
drug resistant cells, drug distribution mimicked that of
sensitivecells. These observations indicate that the nano-
particle formulation is capable of delivering doxorubicin
to the nucleus even for the MDR strains. One of the pro-
posed mechanisms that allow nanoparticles to be effective
against the MDR cells is their ability to overcome drug
efflux pumps such as Pgp in the cell membrane. In order
to assess the effect of doxorubicin loaded nanoparticles
on the expression of Pgp, we undertook western blot anal-
ysis. Several studies report that drug loaded nanopaticles
inhibit MDR1 genes encoding drug efflux pumps, at the
same time downregulating genes responsible for the drug
detoxification and nonspecific resistance [37,38]. Interest-
ingly, after 48 hours of incubation with doxorubicin
loaded nanoparticle, Pgp was upregulated in the drug
resistant cell lines in a dose dependent manner. Recently,
several groups have demonstrated that basal expression of
MDR1 is mechanistically controlled at the chromatin level
and that the promoter methylation is a dominant epige-
netic regulator of MDR1 transcription [39-42]. It seems
that the nanoparticle delivery system caused increased
uptake of doxorubicin and distribution in the nucleus that
led to specific epigenetic modifications within the MDR1
region concomitant with MDR1 upregulation.
The effect of doxorubicin alone or nanoparticle loaded with doxorubicin on KHOS, KHOSR2, U-2OS, andU-2OSR2 was ana- lyzed (A-D) Figure 4
The effect of doxorubicin alone or nanoparticle loaded with doxorubicin on KHOS, KHOSR2, U-2OS, andU-
2OSR2 was analyzed (A-D). Varying concentrations ofdoxorubicin was added and consequently cultured for 5 days. Nano-
particle loaded with doxorubicin showed increasedanti-proliferative activity in both drug sensitive and resistantosteosarcoma 
cell lines in a dose dependent manner. Growth inhibition was assessed by MTT as described under Methods. The experiment 
wasrepeated four times in triplicate.
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Western blot assay was performed to assess the effect of doxorubicin loaded nanoparticle on expression of Pgp Figure 5
Western blot assay was performed to assess the effect of doxorubicin loaded nanoparticle on expression of 
Pgp. The expression of Pgp gradually increased along with the increase in the concentration of doxorubicin on both MDR 
osteosarcoma cell lines.
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Cleavage of PARP was detected using western blot assay Figure 6
Cleavage of PARP was detected using western blot assay. Significant increase in apoptosis was observed for drug sen-
sitive (A) and multidrug resistant osteosarcoma cells (B) when they were treated with doxorubicin loaded nanoparticle. Bar 
graphs represent the result of semiquantification by reverse image scanning densitometry with PhotoShop 7.0 (C, D). P values 
are shown as follows: *P < 0.05.
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Several in vitro studies have suggested that nanoparticle-
drug conjugates induce stronger activation of apoptosis-
signaling pathways compared with free doxorubicin
[37,43]. In contrast, others indicate that cell death
induced by the same conjugates occurs primarily bynecro-
sis [44].
In our study, nanoparticles loaded with doxorubicin
showed increased apoptosis compared to free doxoru-
bicin, supporting the former results. An additional topic
of current investigation is the co-administration of con-
ventional chemotherapy with an efflux pump inhibitor
combined with nanoparticles. There have been reports of
sequential or concurrent administration of separate Pgp
inhibitors and anticancer drugs [45], but this method can-
not guarantee the co-action of intended drugs in the same
cancer cells due to their different pharmacokinetics and
tissue disposition. Introduction of use of nanoparticle
based systems could improve the drug uptake and cyto-
toxity due to the coexistence of the chemosensitizer, anti-
cancer drugs, and perhaps short nucleic acids such as
MDR1siRNA in the same cell, but the precise mechanism
of interaction warrants further investigation.
Conclusion
Doxorubicin loaded dextran nanoparticle has resulted in
a new cancer chemotherapeutic formulation. The indis-
criminate ability of the formulation allows it to obliterate
both wild type and the MDR osteosarcoma cells in vitro
by drug accumulation in the nucleus and increased levels
of apoptosis.
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Caspase-3/7 activity was measured as a second parameter of apoptotic cell death Figure 7
Caspase-3/7 activity was measured as a second parameter of apoptotic cell death. KHOS (A) and KHOSR2 (B) 
showed significant increase in apoptosis when they were treated with doxorubicin loaded nanoparticle. The experiment was 
repeated three times in triplicate. P values are shown as follows: *P < 0.05.
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